LAB — Standard Biotools Balance Sheet
0.000.00%
- $439.62m
- $147.05m
- $174.43m
- 31
- 42
- 42
- 31
Annual balance sheet for Standard Biotools, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 68.5 | 28.5 | 166 | 115 | 293 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 25.4 | 18.3 | 17.3 | 19.7 | 33.6 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 118 | 72.1 | 209 | 158 | 376 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 55.6 | 65.2 | 59.5 | 54.9 | 71.4 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 325 | 275 | 390 | 323 | 612 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 54.2 | 49.6 | 43.4 | 109 | 65.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 186 | 181 | 161 | 160 | 141 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 139 | 94.6 | 230 | 163 | 472 |
Total Liabilities & Shareholders' Equity | 325 | 275 | 390 | 323 | 612 |
Total Common Shares Outstanding |